J
Jose A. Tallaj
Researcher at University of Alabama at Birmingham
Publications - 136
Citations - 3035
Jose A. Tallaj is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Heart failure & Ventricular assist device. The author has an hindex of 28, co-authored 127 publications receiving 2555 citations. Previous affiliations of Jose A. Tallaj include Brigham and Women's Hospital & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Report from a consensus conference on antibody-mediated rejection in heart transplantation
Jon A. Kobashigawa,María G. Crespo-Leiro,Stephan M. Ensminger,Hermann Reichenspurner,Annalisa Angelini,Gerald J. Berry,Margaret Burke,Lawrence S.C. Czer,Nicola E. Hiemann,Abdallah G. Kfoury,Donna Mancini,Paul Mohacsi,Jignesh Patel,Naveen L. Pereira,Jeffrey L. Platt,Elaine F. Reed,Nancy L. Reinsmoen,E. Rene Rodriguez,Marlene L. Rose,Stuart D. Russell,Randy Starling,Nicole Suciu-Foca,Jose A. Tallaj,David O. Taylor,Adrian B. Van Bakel,Lori J. West,Adriana Zeevi,Andreas Zuckermann +27 more
TL;DR: A clinical definition for AMR (cardiac dysfunction and/or circulating donor-specific antibody) was no longer believed to be required due to recent publications demonstrating that asymptomatic (no cardiac dysfunction) biopsy-proven AMR is associated with subsequent greater mortality and greater development of cardiac allograft vasculopathy.
Journal ArticleDOI
A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure.
Ali Ahmed,Faiez Zannad,Thomas E. Love,Jose A. Tallaj,Jose A. Tallaj,Mihai Gheorghiade,Olaniyi J. Ekundayo,Bertram Pitt +7 more
TL;DR: In a cohort of ambulatory chronic systolic and diastolic HF patients who were balanced in all measured baseline covariates, serum potassium <4 mEq/L was associated with increased mortality, with a trend towards increased hospitalization.
Journal ArticleDOI
Cardiovascular events in patients with fabry disease natural history data from the fabry registry.
Manesh R. Patel,Franco Cecchi,Marta Cizmarik,Ilkka Kantola,Aleš Linhart,Kathy Nicholls,Jörg Strotmann,Jose A. Tallaj,Thi Chien Tran,Michael West,Dana Beitner-Johnson,Ademola K. Abiose +11 more
TL;DR: All patients with Fabry disease should be monitored for possible CV risk factors, particularly hypertension and left ventricular hypertrophy, which were the risk factors most strongly associated with CV events.
Journal ArticleDOI
INTERMACS Analysis of Stroke During Support With Continuous-Flow Left Ventricular Assist Devices: Risk Factors and Outcomes
Deepak Acharya,Renzo Y. Loyaga-Rendon,Charity J. Morgan,Kara A Sands,Salpy V. Pamboukian,Indranee Rajapreyar,William L. Holman,James K. Kirklin,Jose A. Tallaj +8 more
TL;DR: Despite improvements in LVAD technology, stroke-related morbidity and mortality is substantial and further investigation is necessary to decrease the risk of this devastating complication.
Journal ArticleDOI
Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.
Thomas J. Ryan,Emily C. Rothstein,Inmaculada Aban,Jose A. Tallaj,Jose A. Tallaj,Ahsan Husain,Pamela A. Lucchesi,Louis J. Dell'Italia,Louis J. Dell'Italia +8 more
TL;DR: It is suggested that ACE inhibitor-mediated increase in LV BK exacerbates matrix loss and explains why ACE inhibition is ineffective in VO.